The timing regulation of the hair growth phases is quite complex. We name teloptosis the termination of the telogen phase with hair shedding. The initiation of the next anagen I phase is independent from teloptosis. Both events are triggered by distinct factors. Indeed, teloptosis is the result of the loss of adhesion between cells of the club hair and those of its epithelial envelope. Teloptosis synchronization is perceived as telogen effluvium, related or not to shortening of the anagen phase. Subtle changes leading to early or delayed teloptosis affect hair density. It is possible to distinguish two types of telogen hairs on a trichogram. Those with an epithelial sheath indicate strong binding, suggesting early telogen, whereas the absence of an epithelial sheath indicates loose binding, conveying teloptosis.

Keywords:
Hair, Teloptosis, Alopecia, Balding
1.
Piérard-Franchimont C, Piérard GE: A propos du follicule pileux et du cycle pilaire: considérations récentes. Rev Méd Liège 1997;52:671–674.
2.
Piérard-Franchimont C, Piérard GE: Cycle de croissance pilaire et évaluation d’une alopécie. Praxis 1997;86:979–981.
3.
Stenn KS: Growth of the hair follicle: A cycling and regenerating biological system; Chuong CM (ed): Molecular Basis of Epithelial Appendage Morphogenesis. Austin, Landes Bioscience, 1998, pp 111–124.
4.
Stenn KS, Nixon AJ, Jahoda CAB, McKay IA, Paus R: What controls hair follicle cycling? Exp Dermatol 1999;8:229–236.
5.
Piérard-Franchimont C, Piérard GE: L’effluvium télogène actinique: une facette de la chronobiologie humaine. Int J Cosmet Sci 1999;21:15–21.
6.
Headington JE: Telogen effluvium: New concepts and review. Arch Dermatol 1993;29:56–63.
7.
Whiting DA: Chronic telogen effluvium: Increased scalp hair shedding in middle-aged women. J Am Acad Dermatol 1996;35:898–906.
8.
Piérard GE, Piérard-Franchimont C, Nikkels-Tassoudji N, Nikkels AF, Saint Léger D: Improvement in the inflammatory aspect of androgenetic alopecia: A pilot study with an antimicrobial lotion. J Dermatol Treat 1996;7:153–157.
9.
Piérard-Franchimont C, De Doncker P, Wallace R, Cauwenbergh G, Piérard GE: Ketoconazole shampoo: Effect of long term use in androgenic alopecia. Dermatology 1998;196:474–477.
10.
Piérard-Franchimont C, Hermanns JF, Degreef H, Piérard GE: From axioms to new insights into dandruff. Dermatology 2000;200:93–98.
11.
Mahé YF, Michelet JF, Billoni N, Jarrousse F, Buan B, Commo S, Saint-Léger D, Bernard BA: Androgenic alopecia and microinflammation. Int J Dermatol 2000;39:576–584.
12.
Heng MCY, Levine S, Fine H, Allen SG, Heng MK: Expression of the L-fucose moiety on infrainfundibular follicular keratinocytes of terminal follicles, its decreased expression on vellus and indeterminate follicles of androgenic alopecia and re-expression in drug-induced hair regrowth. J Invest Dermatol 1992;98:73–78.
13.
Bohm M, Luger TA: The pilosebaceous unit is part of the skin immune system. Dermatology 1998;196:76–79.
14.
Christoph T, Müller-Röver S, Audring H, Tobin DJ, Hermes B, Cotsarelis G, Rückert R, Paus R: The human hair follicle immune system: Cellular composition and immune privilege. Br J Dermatol 2000;142:862–873.
15.
Ramos-e-Silva M: Male pattern hair loss: Prevention rather than regrowth. Int J Dermatol 2000;39:728–731.
© 2001 S. Karger AG, Basel
2001
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.